Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms

BACKGROUND: To evaluate the clinical and prognostic value of PET/CT with combination of (68)Ga-DOTATATE and (18)F-FDG in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). METHOD: 83 patients of GEP-NENs who underwent (68)Ga-DOTATATE and (18)F-FDG PET/CT were enrolled between June 2013 and December 2016. Well-differentiated (WD) NETs are divided into group A (Ki-67 < 10%) and group B (Ki-67 ≥ 10%), and poorly differentiated (PD) NECs are defined as group C. The relationship between PET/CT results and clinicopathological characteristics was retrospectively investigated. RESULT: For groups A/B/C, the sensitivities of (68)Ga-DOTATATE and (18)F-FDG were 78.8%/83.3%/37.5% and 52.0%/72.2%/100.0%. A negative correlation between Ki-67 and SUV(max) of (68)Ga-DOTATATE (R = −0.415; P ≤ 0.001) was observed, while a positive correlation was noted between Ki-67 and SUV(max) of (18)F-FDG (R = 0.683; P ≤ 0.001). 62.5% (5/8) of patients showed significantly more lesions in the bone if (68)Ga-DOTATATE was used, and 22.7% (5/22) of patients showed more lymph node metastases if (18)F-FDG was used. CONCLUSIONS: The sensitivity of dual tracers was correlated with cell differentiation, and a correlation between Ki-67 and both SUV(max) of PET-CTs could be observed. (68)Ga-DOTATATE is suggested for WD-NET and (18)F-FDG is probably suitable for patients with Ki-67 ≥ 10%.